Skip to content

Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV

Study on Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04974424
Enrollment
20000
Registered
2021-07-23
Start date
2021-01-01
Completion date
2023-12-01
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasm

Brief summary

Most uterine cervical high-risk human papillomavirus (HPV) infections are transient, with only a small fraction developing into cervical cancer. Family aggregation studies and heritability estimates suggest a significant inherited genetic component. Candidate gene studies and previous genome-wide association studies (GWASs) report associations between the HLA region and cervical cancer. Adopting a genome-wide approach, we aimed to establish an early warning model for a high-risk population of cervical cancer.

Interventions

None listed

Sponsors

Women's Hospital School Of Medicine Zhejiang University
CollaboratorOTHER
Obstetrics & Gynecology Hospital of Fudan University
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
Wuhan Central Hospital
CollaboratorOTHER
Third Military Medical University
CollaboratorOTHER
Xiangyang Central Hospital
CollaboratorOTHER
Shenzhen Second People's Hospital
CollaboratorOTHER
Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* (1) Case group a) Aged 25-75 years. b) Han nationality. c) Patients with cervical cancer or cervical precancerous lesions above CIN2 diagnosed by biopsy or postoperative pathological diagnosis. * (2) Control group: a) Aged 25-75 years. b) Han nationality. c) No family history of cervical cancer or precancerous lesions. d) The results of TCT examination showed no abnormality.

Exclusion criteria

* (1) suffering from other neoplastic diseases. * (2) pregnant women. * (3) those with a history of bone marrow transplantation.

Design outcomes

Primary

MeasureTime frameDescription
Significant loci of genetic variation2The impact of genetic variance on predisposition to cervical cancer

Countries

China

Contacts

Primary ContactDing Ma, MD, PhD
dma@tjh.tjmu.edu.cn0086-27-836268

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026